Table 1.

Baseline demographic and clinical characteristics.

	Crohn’s disease patients	Ulcerative colitis patients
n	64	36
Females, n (%)	31 (48.4)	18 (50)
Males, n (%)	33 (51.6)	18 (50)
Age, median years (range)	40.5 (18–77)	44.0 (37–53)
Age at diagnosis, median years (IQR)	26 (19–37)	29 (25–44)
Smoking status, n (%)
Never smoked	43 (67.2)	25 (69.4)
Ex-smoker	11 (17.2)	7 (19.4)
Current smoker	10 (15.6)	4 (11.2)
Extraintestinal manifestations, n (%)	20 (31.3)	10 (27.7)
Prior medical exposure, n (%)
Thiopurines	33 (51.6)	19 (52.8)
Methotrexate	20 (31.3)	5 (13.9)
Concomitant medication use
Thiopurines	27 (42.2)	13 (36.1)
Methotrexate	14 (21.8)	3 (8.3)
Steroids	10 (15.6)	5 (13.9)
Time from diagnosis to end of follow up in years (median, IQR)	11 (6–14)	10 (6–13)
Duration of original IFX therapy in months (median, IQR)	70 (44–85)	50 (22–76)
Crohn’s disease
Age at diagnosis, n (%)	A1 (diagnosed <17 years of age)	8 (12.5)
	A2 (diagnosed 17–40 years of age)	46 (71.9)
	A3 (diagnosed >40 years of age)	10 (25.6)
Disease location at diagnosis, n (%)	L1 (ileal)	16 (25)
	L2 (colonic)	27 (42.2)
	L3 (ileocolonic)	18 (28.2)
	L3 (ileocolonic) + L4 (upper gastrointestinal tract)	3 (4.7)
Disease behavior, n (%)	B1 (nonstricturing, nonpenetrating)	39 (60.9)
	B2 (stricturing)	12 (18.8)
	B3 (penetrating)	13 (20.3)
Perianal disease, n (%)		28 (43.8)
Extraintestinal manifestations, n (%)		20 (31.3)
Median Harvey–Bradshaw index prior to switch (IQR)		1 (1–3)
Ulcerative colitis
Extent, n (%)	E1 (proctitis)	13 (36.1)
	E2 (left-sided colitis)	11 (30.6)
	E3 (pancolitis)	12 (33.3)
Severity, n (%)	S1 (mild)	13 (36.1)
	S2 (moderate)	17 (47.2)
	S3 (severe)	6 (16.7)
Extraintestinal manifestations, n (%)		10 (27.7)
Median partial Mayo score prior to switch (IQR)		2 (1–3)

IFX, infliximab; IQR, interquartile range.